This is a routine resale registration filing that does not change the company's fundamentals. The large overhang of registered shares (75.2M vs 107.4M outstanding) could create near-term selling pressure. Monitor the pace of insider selling and any updates on SimpleScreen CRC commercial uptake under Abbott's commercialization.
Executive Summary
Freenome filed an S-1 registration statement to register 75,188,742 shares of common stock for resale by selling securityholders, including shares issued in connection with its July 2026 de-SPAC business combination with Perceptive Capital Solutions Corp. The company is an early cancer detection company whose FDA-approved SimpleScreen CRC blood test is being commercialized by Abbott. The company will not receive proceeds from the resale, but may receive up to ~$36.3M from cash exercise of options and warrants. The filing is a routine registration of shares for resale and does not represent a new capital raise or a change in the company's financial condition.
Key Facts
- Freenome registered 75,188,742 shares of common stock for resale by selling securityholders.
- The shares include PIPE shares, sponsor shares, merger consideration shares, option shares, RSU shares, Roche conversion shares, and a private warrant.
- Freenome will not receive any proceeds from the sale of shares by selling securityholders.
- The company may receive up to approximately $36.3 million from the cash exercise of options and the private warrant.
- The company's SimpleScreen CRC test received FDA approval in July 2026 and is being commercialized by Abbott in the U.S.
- Freenome completed a de-SPAC business combination with Perceptive Capital Solutions Corp on July 20, 2026.
- As of June 30, 2026, Freenome had an accumulated deficit of $1.5 billion and net losses of $132.6 million for the six months then ended.
- The company believes its existing cash, plus net proceeds from the business combination and a $100M milestone payment, will fund operations through 2028.
Financial Impact
Filing registers up to 75.2M shares for resale; no proceeds to company except up to ~$36.3M from option/warrant exercises. Company had $102.0M cash and marketable securities as of June 30, 2026, plus $295.5M net proceeds from de-SPAC and a $100M milestone payment from Abbott.
Risk Factors
- Potential near-term selling pressure from the large block of registered shares (75.2M shares, ~70% of current outstanding).
- Company continues to generate significant operating losses ($132.6M net loss in H1 2026) and has an accumulated deficit of $1.5B.
- Commercial success of SimpleScreen CRC is unproven and depends on Abbott's execution and market adoption.
- Future capital needs may require additional dilutive financing.
- Reliance on sole suppliers (Illumina, New England Biolabs) for key reagents and sequencers.
Market Snapshot
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001140361-26-033585 |
| Document: ny20080283_ex107.htm | 0001140361-26-033585 |
| Document: ny20080283x1_ex5-1.htm | 0001140361-26-033585 |
| Document: ny20080283x1_ex23-1.htm | 0001140361-26-033585 |
| Document: ny20080283x1_ex23-2.htm | 0001140361-26-033585 |
| Document: 0001140361-26-033585-index-headers.html | 0001140361-26-033585 |
| Document: 0001140361-26-033585-index.html | 0001140361-26-033585 |
| Document: 0001140361-26-033585.txt | 0001140361-26-033585 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $14.06 $14.01 | ▼ −0.36% | ▼ −0.88% | $12.70 (−9.67%) |
Oct 15, 2026 10d ago | Press Release | $11.75 $12.57 | ▲ +6.98% | ▲ +6.56% | $12.70 (+8.09%) |
Aug 28, 2026 8w ago | EFFECT | $14.79 $14.79 | · 0.00% | ▲ +0.30% | $12.70 (−14.13%) |
Aug 18, 2026 9w ago | S-1 | $13.63 $13.51 | ▼ −0.88% | ▼ −0.04% | $12.70 (−6.82%) |
Jul 27, 2026 12w ago | 3 | $10.77 $10.06 | ▼ −6.59% | ▼ −5.05% | $12.70 (+17.92%) |
Jul 23, 2026 13w ago | 8-K | $11.24 $11.38 | ▲ +1.25% | ▲ +1.22% | $12.70 (+12.99%) |
Jul 20, 2026 13w ago | Press Release | $13.01 $13.14 | ▲ +1.00% | ▲ +1.12% | $12.70 (−2.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers